Literature DB >> 18287607

Learning from aprotinin--mandatory trials of comparative efficacy and safety needed.

Wayne A Ray.   

Abstract

Mesh:

Substances:

Year:  2008        PMID: 18287607     DOI: 10.1056/NEJMe0800268

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Perioperative safety of aprotinin in coronary artery bypass graft surgery: is there life after BART?

Authors:  John G Augoustides
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 2.  Platelet-rich-plasmapheresis for minimising peri-operative allogeneic blood transfusion.

Authors:  Paul A Carless; Fraser D Rubens; Danielle M Anthony; Dianne O'Connell; David A Henry
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

3.  Aprotinin exacerbates left ventricular dysfunction after ischemia/reperfusion in mice lacking tumor necrosis factor receptor I.

Authors:  Michel J Sabbagh; J Michael Looper; Juozas A Zavadzkas; Robert E Stroud; Rachael L Ford; William T Rivers; Christine N Koval; Matthew D McEvoy; Scott T Reeves; Francis G Spinale
Journal:  J Cardiovasc Pharmacol       Date:  2008-10       Impact factor: 3.105

4.  Aprotinin and classic wound drainage are unnecessary in total hip replacement - a prospective randomized trial.

Authors:  F Fleischmann; C Matuschek; K Orth; P A Gerber; R Mota; W T Knoefel; M Peiper; M Schick; M van Griensven; Edwin Bölke; W Fleischmann
Journal:  Eur J Med Res       Date:  2011-01-27       Impact factor: 2.175

5.  The aprotinin saga and the risks of conducting meta-analyses on small randomised controlled trials - a critique of a Cochrane review.

Authors:  Måns Rosén
Journal:  BMC Health Serv Res       Date:  2009-02-19       Impact factor: 2.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.